Back to News
Market Impact: 0.22
BoomRay Pharma, Novartis Ink Radioligand Therapy Licensing Deal Worth Up To $900 Mln
Source: Nasdaq
Healthcare & BiotechM&A & RestructuringPrivate Markets & Venture
BoomRay Pharmaceuticals signed an exclusive global license agreement with Novartis Pharma for an undisclosed preclinical radioligand-therapy asset. The deal expands BoomRay's early-stage oncology pipeline, though financial terms, development milestones and the specific asset were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NVS0.35
More News
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- The race is on to build the first fusion power plant — and Europe is looking to Japan for help
- Fox completes its $22B acquisition of Roku
- Fox wraps up its $22 billion Roku deal
- Fox completes $22 billion Roku deal to expand digital reach